Novo Holdings co-leads €40m fundraising to scale MATR Foods’ production of organic plant-based meat alternatives

/in

Financing co-led by Novo Holdings and EIFO Proceeds to fund the scaling and internationalisation of MATR’s clean label plant products Includes the development of new 4,000-tonne plant, expected to be operational by 2027 Copenhagen, Denmark, 21 October 2025 – MATR Foods (MATR), the leader in next generation fermented plant-based meat alternatives, today announced the successful completion of […]

Read more

Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials

/in

Financing will support the full execution of Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD) Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment for PD, in healthy volunteers Phase Ib study due to start in H1 2026 Cambridge, UK – October 15, 2025 – […]

Read more

Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications

/in

Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London’s lab, a leader in covalent drug design Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals Integration into Actithera’s platform to support design of next-generation radioligand therapies across oncology indications Cambridge, MA and Oslo, […]

Read more

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points

/in

Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]

Read more

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

/in

Results presented today at ESGCT 2025 PARIS, France, LUND, Sweden (October 10, 2025) – Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV […]

Read more
© Optimum Strategic Communications.